Does saffron work as well as sertraline for depression in older adults?
In one six week trial, yes. A double-blind, randomized study of 50 older outpatients with major depressive disorder compared saffron 60 mg/day against the SSRI sertraline 100 mg/day and found that depression symptoms fell over time in both groups, with no advantage or disadvantage for either treatment. This is a single head to head trial, not a meta-analysis, and it measured depression only.
Participants had a mean age of 65 years, and 70% were male. Experts rated depression with the Hamilton Depression Rating Scale at baseline, week 2, week 4, and week 6.
What the data show:
- Comparison: Saffron 60 mg/day versus sertraline 100 mg/day for six weeks
- Population: 50 older outpatients with major depressive disorder, mean age 65 years, 70% male
- Outcome measure: Hamilton Depression Rating Scale at baseline, week 2, week 4, and week 6
- Result: Depression symptoms decreased over time in both groups, with no advantages or disadvantages for saffron or sertraline
The study was published in Psychiatry Research in 2019 and was designed to fill a specific gap: the authors note that saffron had been studied for depression in young and middle-aged adults, but not in older people.
Dr. Kumar’s Take
I like this study for one reason: it is a direct comparison. Most botanical trials pit a supplement against placebo, which tells me whether something beats nothing. This one put saffron next to sertraline at a full therapeutic dose in the population where the question actually matters, older adults with major depression, and both arms improved with neither pulling ahead.
I want to be precise about what that means. Fifty patients over six weeks is a small, short trial, and a finding of no difference between two active treatments is not the same as proof that they are interchangeable. A study this size cannot detect a modest advantage in either direction. There was also no placebo arm, so I cannot separate drug effect from the natural course of a six week trial.
Where I find it useful is in older patients who are reluctant to start a synthetic antidepressant, which is the population the authors themselves point to. This trial gives me something concrete to discuss with them rather than a vague appeal to natural remedies. It does not tell me saffron should replace an SSRI in someone with severe or high risk depression, and I would not treat it that way.
Study Snapshot
This was a double-blind, randomized intervention study. Fifty older outpatients with major depressive disorder, mean age 65 years and 70% male, were randomly assigned to either saffron 60 mg/day or sertraline 100 mg/day for six consecutive weeks. Experts, rather than the patients themselves, rated the degree of depression using the Hamilton Depression Rating Scale. Ratings were taken at four timepoints: baseline, week 2, week 4, and week 6, the end of the study.
Results in Real Numbers
Symptoms of depression decreased over time in the study population. Comparing the two arms, the researchers found no advantages or disadvantages for either the saffron condition or the sertraline condition.
The authors conclude that both saffron and sertraline have the potential to significantly decrease symptoms of depression, and that the result is clinically relevant because major depressive disorder in older people is a health concern. They frame saffron as a meaningful option for older patients who may be more reluctant to use synthetic drugs.
The trial ran for six weeks, so it speaks to short term symptom change. It does not tell me anything about how either treatment performs over months of maintenance.
Who Benefits Most
Older adults with major depressive disorder are the population this trial actually enrolled, so they are the group the findings apply to most directly. The authors single out older patients who are hesitant about synthetic antidepressants as the people most likely to find saffron useful.
Patients and clinicians looking for head to head comparison data, rather than another placebo controlled supplement trial, will find this study more informative than most of the saffron literature. Anyone extrapolating to younger adults, to anxiety, or to treatment beyond six weeks is going past what this trial tested.
Safety, Limits, and Caveats
The trial enrolled 50 patients over six weeks, and 70% of participants were male, so the findings are not broadly generalizable. There was no placebo group, which means both arms improving cannot be fully attributed to the treatments.
A six week window is short for a depression trial. Relapse, long term tolerability, and sustained response were outside its scope.
Saffron supplements vary considerably in standardization and potency between products, so a commercial product is not automatically equivalent to what was given in a controlled trial. Anyone considering saffron for depression should do so with a physician, particularly alongside other medications, and no one should stop a prescribed antidepressant on their own.
Practical Takeaways
- Treat this as one small head to head trial in older adults, not as settled evidence that saffron matches SSRIs generally
- The trial dose was 60 mg of saffron per day, compared against sertraline 100 mg per day, over six weeks
- The population studied was older outpatients with major depressive disorder, mean age 65
- Depression was measured by clinician rating on the Hamilton Depression Rating Scale, not by self report
- Discuss saffron with your physician before starting it, and never discontinue a prescribed antidepressant without medical supervision
What This Means for Depression Treatment
This trial adds direct comparative data in a group that saffron research had skipped: older adults with major depression. Over six weeks, saffron at 60 mg/day and sertraline at 100 mg/day were associated with declining depression scores, with neither showing an edge.
That is a reasonable starting point for a conversation, not a conclusion. Confirming it would take larger trials, longer follow up, and a placebo arm. Until then I read this as encouraging preliminary evidence for saffron in older patients with depression, and nothing more definitive than that.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
Is saffron as effective as prescription antidepressants?
In this six week trial of 50 older outpatients with major depressive disorder, saffron 60 mg/day and sertraline 100 mg/day both saw depression symptoms decrease over time, with no advantage or disadvantage for either. That is one small study, so I would not generalize it beyond older adults or beyond six weeks.
Who was studied?
Fifty older outpatients with major depressive disorder, mean age 65 years, 70% of them male, in a double-blind randomized trial.
What dose of saffron was used?
The trial used 60 mg of saffron per day for six weeks, compared with sertraline 100 mg per day. Dosing decisions should be made with a physician.
Bottom Line
In a double-blind randomized trial of 50 older outpatients with major depressive disorder, six weeks of saffron 60 mg/day and six weeks of sertraline 100 mg/day both coincided with falling depression scores, with no advantage for either treatment. It is a small, short, single trial, and it supports saffron as worth studying further in older adults, not as an established substitute for an SSRI.
